Breaking News Instant updates and real-time market news.

DATA

Tableau

$164.13

-3.34 (-1.99%)

, CRM

Salesforce

$150.12

-2.63 (-1.72%)

07:49
06/12/19
06/12
07:49
06/12/19
07:49

Citi sees competitive bidding process for Tableau as unlikely

Citi analyst Tyler Radke downgraded Tableau Software (DATA) to Neutral from Buy with a $178 price target to reflect the pending takeover by Salesforce (CRM). The analyst continues to see a competitive bidding process as unlikely. Radke continues to favor Alteryx (AYX) as his top pick given the company's combination of "strong top-line growth paired with near best-in-class unit economics and profitability." Further, he believes Alteryx's market opportunity may be underestimated. Talend (TLND) moves to the analyst's second pick.

DATA

Tableau

$164.13

-3.34 (-1.99%)

CRM

Salesforce

$150.12

-2.63 (-1.72%)

AYX

Alteryx

$95.89

-1.83 (-1.87%)

TLND

Talend

$39.94

-0.57 (-1.41%)

  • 17

    Jun

  • 23

    Jun

DATA Tableau
$164.13

-3.34 (-1.99%)

06/12/19
FANA
06/12/19
DOWNGRADE
FANA
Neutral
Tableau downgraded to Neutral from Outperform at First Analysis
First Analysis analyst Frank Sparacino downgraded Tableau Software (DATA) to Neutral from Outperform citing the "high probability" of the Salesforce (CRM) buyout closing. Further, the analyst maintains a Neutral rating on MicroStrategy (MSTR). He does not see the company taking part in any future consolidation as an acquirer or target. Further, any potential benefit to ongoing sales cycles from takeover disruption with Tableau and Looker is likely to be minor, Sparacino tells investors in a research note.
06/11/19
JMPS
06/11/19
NO CHANGE
JMPS
Outperform
JMP says Tableau and Looker deals have 'positive implications' for Domo, Alteryx
JMP Securities analyst Patrick Walravens said this week's announcements of deals for Tableau (DATA) and Looker reminds him of 2007, when three leading analytics companies at the time were acquired over a period of eight months. He also believes the deals have "positive lateral implications" for Domo (DOMO), Alteryx (AYX) and private companies such as Sisense. Walravens have Outperform ratings on both Domo and Alteryx.
06/11/19
06/11/19
DOWNGRADE

Neutral
Tableau downgraded to Neutral at BTIG on Salesforce acquisition
As previously reported, BTIG analyst Edward Parker downgraded Tableau (DATA) to Neutral after Salesforce (CRM) announced its intention to acquire the company in an all-stock transaction. The analyst notes that the "very low" regulatory risk to deal closure is offset by the unlikely possibility for another suitor to outbid Salesforce. Parker adds that in the absence of a "meaningful premium" potential to Tableau shares following the Salesforce announcement, a Neutral rating is warranted.
06/12/19
SBSH
06/12/19
DOWNGRADE
Target $178
SBSH
Neutral
Tableau downgraded to Neutral from Buy at Citi
Citi analyst Tyler Radke downgraded Tableau Software (DATA) to Neutral from Buy with a $178 price target to reflect the pending takeover by Salesforce (CRM).
CRM Salesforce
$150.12

-2.63 (-1.72%)

06/11/19
RHCO
06/11/19
NO CHANGE
Target $189
RHCO
Buy
Salesforce price target raised to $189 from $183 at SunTrust
SunTrust analyst Terry Tillman raised his price target on Salesforce (CRM) to $189 and kept his Buy rating with a positive view of its announced acquisition of Tableau (DATA). The analyst notes that while the deal introduces some execution risk, it also "brings together integration, customer, and data technologies into a Customer 360 platform story." Tillman adds that the "strong core business" expected on a seasonal basis for the second half of this year, along with expected execution from the acquired MuleSoft and Tableau assets, represent "material catalysts" for Salesforce.
AYX Alteryx
$95.89

-1.83 (-1.87%)

06/07/19
GSCO
06/07/19
INITIATION
Target $111
GSCO
Buy
Alteryx initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Christopher Merwin started Alteryx with a Buy rating and $111 price target.
05/02/19
COWN
05/02/19
NO CHANGE
Target $103
COWN
Outperform
Alteryx guidance remains conservative after increase, says Cowen
Cowen analyst J. Derrick Wood noted that Alteryx management raised their FY19 revenue forecast by $10M after the company reported strong Q1 results, but he believes the guidance remains conservative, citing several factors that give him confidence in the company's ability to sustain strong growth momentum. He also thinks Alteryx is positioned to see significant growth in deal sizes over the next couple of years. Wood keeps an Outperform rating on Alteryx and raised his price target on the stock to $103 from $97 following the Q1 report.
06/12/19
NEED
06/12/19
NO CHANGE
Target $120
NEED
Buy
Alteryx price target raised to $120 from $108 at Needham
Needham analyst Jack Andrews raised his price target on Alteryx shares to $120 from $108 after attending the company's annual customer conference, during which management provided an updated long-term operating model. Additionally, customer conversations were "extraordinarily positive," Andrews tells investors. He maintains a Buy rating on Alteryx, noting also that the company introduced three new types of functionality during the event.
TLND Talend
$39.94

-0.57 (-1.41%)

01/08/19
KEYB
01/08/19
NO CHANGE
KEYB
Microsoft, Salesforce among top Software stocks to own in 2019, says KeyBanc
KeyBanc analyst Brent Bracelin notes that despite challenging market conditions during Q4, the 45 software applications in his coverage universe outperformed the broader market by a wide margin. While industry conditions for application software appear more volatile entering 2019, the analyst sees a favorable backdrop for modern cloud-based applications with recurring subscription-based revenue models and continues to favor growth over value. His top software application stocks to own for 2019 include Microsoft (MSFT), Synopsys (SNPS), PTC (PTC), RealPage (RP), Talend (TLND), Salesforce (CRM), Shopify (SHOP), Twilio (TWLO), Avalara (AVLR).
03/25/19
BTIG
03/25/19
NO CHANGE
Target $62
BTIG
Buy
Talend price target raised to $62 from $50 at BTIG
BTIG analyst Edward Parker raised his price target on Talend to $62 and kept his Buy rating, saying he is turning "more comfortable" that the company is "shrugging off Big Data jitters and that demand fundamentals are much healthier than the revenue accounting would suggest." While Parker expects "transitional headwinds" to impact Talend's topline growth rate for several more quarters, he sees its "aggressive pivot towards cloud data integration" as the right strategy, adding that the company's valuation has also "recovered meaningfully".
04/08/19
KEYB
04/08/19
NO CHANGE
Target $65
KEYB
Overweight
Talend price target raised to $65 from $52 at KeyBanc
KeyBanc analyst Brent Bracelin raised his price target for Talend to $65 from $52 as he is encouraged by early signs of cloud success based on partner feedback. The analyst reiterates an Overweight rating on the shares.
06/07/19
GSCO
06/07/19
INITIATION
Target $39
GSCO
Sell
Talend initiated with a Sell at Goldman Sachs
Goldman Sachs analyst Christopher Merwin started Talend with a Sell rating and $39 price target.

TODAY'S FREE FLY STORIES

IRE

Bank of Ireland

$0.00

(0.00%)

05:24
06/20/19
06/20
05:24
06/20/19
05:24
Upgrade
Bank of Ireland rating change  »

Bank of Ireland upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOC

Physicians Realty Trust

$18.27

0.095 (0.52%)

05:23
06/20/19
06/20
05:23
06/20/19
05:23
Initiation
Physicians Realty Trust initiated  »

Physicians Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTA

Healthcare Trust

$29.18

0.16 (0.55%)

05:23
06/20/19
06/20
05:23
06/20/19
05:23
Initiation
Healthcare Trust initiated  »

Healthcare Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

HR

Healthcare Realty Trust

$33.14

0.26 (0.79%)

05:22
06/20/19
06/20
05:22
06/20/19
05:22
Initiation
Healthcare Realty Trust initiated  »

Healthcare Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

SCRYY

Scor

$0.00

(0.00%)

05:22
06/20/19
06/20
05:22
06/20/19
05:22
Upgrade
Scor rating change  »

Scor upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMS

Fresenius Medical

$39.49

1.175 (3.07%)

05:20
06/20/19
06/20
05:20
06/20/19
05:20
Upgrade
Fresenius Medical rating change  »

Fresenius Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$20.63

0.1 (0.49%)

05:16
06/20/19
06/20
05:16
06/20/19
05:16
Initiation
HP Inc. initiated  »

Deutsche Bank starts HP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 01

    Jul

  • 02

    Jul

  • 03

    Jul

  • 04

    Jul

DELL

Dell Technologies

$53.39

1.88 (3.65%)

05:15
06/20/19
06/20
05:15
06/20/19
05:15
Initiation
Dell Technologies initiated  »

Deutsche Bank starts Dell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

FNMA

Fannie Mae

05:12
06/20/19
06/20
05:12
06/20/19
05:12
Initiation
Fannie Mae initiated  »

Fannie Mae initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMCC

Freddie Mac

$0.00

(0.00%)

05:12
06/20/19
06/20
05:12
06/20/19
05:12
Initiation
Freddie Mac initiated  »

Freddie Mac initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$197.87

-0.65 (-0.33%)

05:12
06/20/19
06/20
05:12
06/20/19
05:12
Initiation
Apple initiated  »

Deutsche Bank, fearing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBLU

JetBlue

$19.05

-0.21 (-1.09%)

05:07
06/20/19
06/20
05:07
06/20/19
05:07
Recommendations
JetBlue analyst commentary  »

JetBlue price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VYGR

Voyager Therapeutics

$27.87

0.05 (0.18%)

, SNY

Sanofi

$44.11

0.99 (2.30%)

05:05
06/20/19
06/20
05:05
06/20/19
05:05
Recommendations
Voyager Therapeutics, Sanofi, Neurocrine analyst commentary  »

Voyager Therapeutics…

VYGR

Voyager Therapeutics

$27.87

0.05 (0.18%)

SNY

Sanofi

$44.11

0.99 (2.30%)

NBIX

Neurocrine

$85.47

-0.28 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 16

    Sep

ORCL

Oracle

$52.69

-0.19 (-0.36%)

05:02
06/20/19
06/20
05:02
06/20/19
05:02
Recommendations
Oracle analyst commentary  »

Oracle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BFAM

Bright Horizons

$141.18

1.73 (1.24%)

04:59
06/20/19
06/20
04:59
06/20/19
04:59
Upgrade
Bright Horizons rating change  »

Bright Horizons upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENBL

Enable Midstream

04:56
06/20/19
06/20
04:56
06/20/19
04:56
Initiation
Enable Midstream initiated  »

Enable Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GHDX

Genomic Health

$54.26

-0.04 (-0.07%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Upgrade
Genomic Health rating change  »

Genomic Health upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

SMG

Scotts Miracle-Gro

$98.53

0.4 (0.41%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Scotts Miracle-Gro management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

04:55
06/20/19
06/20
04:55
06/20/19
04:55
General news
Jobless Claims to be reported at 08:30 »

Week of 6/15 Jobless…

CVS

CVS Health

$54.89

0.23 (0.42%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
CVS Health participates in a conference call with Morgan Stanley »

Healthcare Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

CACI

CACI

$206.19

2.03 (0.99%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
CACI to hold a conference call »

Management holds a fiscal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

ASB

Associated Banc-Corp

$20.76

-0.1 (-0.48%)

, BFC

Bank First National

$71.11

-2.38 (-3.24%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Sandler O'Neill to hold a field trip »

Wisconsin Community Bank…

ASB

Associated Banc-Corp

$20.76

-0.1 (-0.48%)

BFC

Bank First National

$71.11

-2.38 (-3.24%)

BWB

Bridgewater Bancshares

$11.38

0.19 (1.70%)

CZWI

Citizens Community Bancorp

$10.83

(0.00%)

FBIZ

First Business Financial

$23.41

-0.09 (-0.38%)

ICBK

County Bancorp

$17.19

(0.00%)

NCBS

Nicolet Bankshares

$61.99

0.19 (0.31%)

WSBF

Waterstone Financial

$16.85

-0.01 (-0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIGI

Selective Insurance

$76.39

0.24 (0.32%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Selective Insurance management to meet with Buckingham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

RVNC

Revance

$11.57

0.09 (0.78%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Revance management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 10

    Jul

  • 11

    Jul

AJG

Arthur J. Gallagher

$86.81

0.775 (0.90%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Arthur J. Gallagher management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.